BRPI0819211A2 - Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo - Google Patents

Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo

Info

Publication number: BRPI0819211A2
Authority: BR; Brazil
Prior art keywords: immunoassay; polynucleotide; antibody; kit; producing
Prior art date: 2007-11-02

Application number

BRPI0819211-1A

Other languages

English (en)

Inventor

Donmienne Doen Mun Leung

Peng Luan

Barbara Anne Swanson

Ying Tang

Derrick Ryan Witcher

Yuping Anthony Cai

Dennis Patrick Gately

Luhong He

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-02

Filing date

2008-10-29

Publication date

2015-06-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40383701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819211(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-29 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2015-06-16 Publication of BRPI0819211A2 publication Critical patent/BRPI0819211A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Hematology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Mycology (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0819211-1A 2007-11-02 2008-10-29 Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo BRPI0819211A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98491007P	2007-11-02	2007-11-02
PCT/US2008/081493 WO2009058797A1 (en)	2007-11-02	2008-10-29	Anti-hepcidin antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI0819211A2 true BRPI0819211A2 (pt)	2015-06-16

Family

ID=40383701

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0819211-1A BRPI0819211A2 (pt)	2007-11-02	2008-10-29	Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo

Country Status (34)

Country	Link
US (3)	US7820163B2 (pt)
EP (2)	EP2527368B1 (pt)
JP (1)	JP5469076B2 (pt)
KR (2)	KR20120107145A (pt)
CN (1)	CN103492414B (pt)
AR (1)	AR069062A1 (pt)
AU (1)	AU2008318850B2 (pt)
BR (1)	BRPI0819211A2 (pt)
CA (1)	CA2704527C (pt)
CL (2)	CL2008003190A1 (pt)
CO (1)	CO6231037A2 (pt)
CR (1)	CR11414A (pt)
CY (1)	CY1113630T1 (pt)
DK (1)	DK2209806T3 (pt)
DO (2)	DOP2010000123A (pt)
EA (1)	EA023406B1 (pt)
ES (1)	ES2392123T3 (pt)
HR (1)	HRP20120870T1 (pt)
IL (1)	IL205355A (pt)
JO (1)	JO2828B1 (pt)
MA (1)	MA31886B1 (pt)
MX (1)	MX2010004841A (pt)
MY (1)	MY155708A (pt)
NZ (2)	NZ598391A (pt)
PE (1)	PE20091261A1 (pt)
PL (1)	PL2209806T3 (pt)
PT (1)	PT2209806E (pt)
RS (1)	RS52592B (pt)
SI (1)	SI2209806T1 (pt)
TN (1)	TN2010000201A1 (pt)
TW (1)	TWI409276B (pt)
UA (1)	UA98983C2 (pt)
WO (1)	WO2009058797A1 (pt)
ZA (1)	ZA201003025B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPWO2008047485A1 (ja) *	2006-10-17	2010-02-18	直久友杉	活性型ヘプシジンを指標とした、鉄代謝異常の診断方法
US8629250B2 (en)	2007-02-02	2014-01-14	Amgen Inc.	Hepcidin, hepcidin antagonists and methods of use
WO2008146903A1 (ja) *	2007-05-31	2008-12-04	Naohisa Tomosugi	活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
PE20091261A1 (es)	2007-11-02	2009-08-17	Lilly Co Eli	Anticuerpos anti-hepcidina
CA2722600C (en) *	2008-05-01	2014-01-21	Amgen Inc.	Anti-hepcidin antibodies and methods of use
UA103032C2 (uk) *	2008-08-06	2013-09-10	Елі Ліллі Енд Компані	Селективні антитіла проти гепсидину-25 та їх застосування
DE102009034150A1 (de) *	2009-07-20	2011-01-27	Fresenius Medical Care Deutschland Gmbh	Adsorbens zur Adsorption von Hepcidin
AR077892A1 (es)	2009-08-20	2011-09-28	Vifor Int Ag	Quinolinas antagonistas de la hepcidina
AR077958A1 (es)	2009-08-27	2011-10-05	Vifor Int Ag	Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es)	2009-09-02	2011-10-05	Vifor Int Ag	Antagonistas de pirimidin y triazin-hepcidina
EP2475643A1 (de)	2009-09-07	2012-07-18	Vifor (International) Ag	Neue ethandiamin-hepcidin-antagonisten
WO2011029832A1 (de)	2009-09-09	2011-03-17	Vifor (International) Ag	Neue thiazol- und oxazol-hepcidin-antagonisten
WO2011071368A1 (en)	2009-12-11	2011-06-16	Umc St. Radboud	Method for measuring hepcidin
EP3299386A1 (en) *	2010-08-16	2018-03-28	Pieris Pharmaceuticals GmbH	Binding proteins for hepcidin
US20120214803A1 (en)	2011-02-18	2012-08-23	Vifor (International) Ag	Novel Sulfonaminoquinoline Hepcidin Antagonists
EP2791684B1 (en)	2011-12-12	2017-08-23	Pieris Pharmaceuticals GmbH	Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
WO2014152006A2 (en) *	2013-03-15	2014-09-25	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
CA2961917A1 (en)	2014-09-22	2016-03-31	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
CN104945497B (zh) *	2014-11-21	2018-04-03	南京国龙生物科技有限公司	一种新型抗菌肽Hep‑W及其制备方法和应用
EP3261670A4 (en)	2015-02-24	2018-08-01	Rpeptide, LLC	Anti-tau antibodies
WO2016146587A1 (en)	2015-03-13	2016-09-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Hepcidin antagonists for use in the treatment of inflammation
TWI789343B (zh)	2016-02-01	2023-01-11	丹麥商碩騰丹麥有限公司	微流體分析系統、執行分析的微流體匣及方法
WO2018234538A1 (en)	2017-06-23	2018-12-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Hepcidin antagonist or agonist for use in the treatment of dysregulation of mo and/or mn metabolism
ES2759622T3 (es)	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en)	2020-11-04	2022-05-12	Keros Therapeutics, Inc.	Methods of treating iron overload
CN117903311B (zh) *	2024-03-20	2024-10-25	湖南卓润生物科技有限公司	sST2特异性结合蛋白及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3774300A (en)	1999-06-02	2000-12-18	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en)	1999-08-30	2001-07-17	Incyte Genomics, Inc.	Polycyclic aromatic hydrocarbon induced molecules
DE60231804D1 (de) *	2001-05-25	2009-05-14	Inst Nat Sante Rech Med	Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
CN1173737C (zh)	2002-10-21	2004-11-03	钱忠明	Hepcidin(海魄喜定)在制药中的应用
WO2004058044A2 (en)	2002-11-19	2004-07-15	Drg International, Inc.	Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) *	2002-11-19	2011-09-13	Hasan Kulaksiz	Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en)	2002-11-19	2008-08-12	Drg International, Inc.	Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
WO2005033327A2 (en)	2003-09-29	2005-04-14	Biosite Incorporated	Methods and compositions for the diagnosis of sepsis
US7723063B2 (en) *	2004-04-28	2010-05-25	Intrinsic Lifesciences	Methods for measuring levels of bioactive human hepcidin
EP1853630A1 (en)	2004-10-22	2007-11-14	Applied Molecular Evolution Inc.	Methods of optimizing antibody variable region binding affinity
WO2006062685A2 (en)	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
KR101310000B1 (ko)	2005-03-11	2013-09-25	싸이퍼젠 바이오시스템즈, 인코포레이티드	난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
US8629250B2 (en)	2007-02-02	2014-01-14	Amgen Inc.	Hepcidin, hepcidin antagonists and methods of use
WO2009044284A1 (en)	2007-10-02	2009-04-09	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Antibodies specific for human hepcidin
PE20091261A1 (es)	2007-11-02	2009-08-17	Lilly Co Eli	Anticuerpos anti-hepcidina
CA2722600C (en)	2008-05-01	2014-01-21	Amgen Inc.	Anti-hepcidin antibodies and methods of use
UA103032C2 (uk) *	2008-08-06	2013-09-10	Елі Ліллі Енд Компані	Селективні антитіла проти гепсидину-25 та їх застосування

2008
- 2008-10-27 PE PE2008001837A patent/PE20091261A1/es not_active Application Discontinuation
- 2008-10-27 TW TW097141237A patent/TWI409276B/zh not_active IP Right Cessation
- 2008-10-27 JO JO2008486A patent/JO2828B1/en active
- 2008-10-27 AR ARP080104691A patent/AR069062A1/es unknown
- 2008-10-27 CL CL2008003190A patent/CL2008003190A1/es unknown
- 2008-10-29 ES ES08844586T patent/ES2392123T3/es active Active
- 2008-10-29 PL PL08844586T patent/PL2209806T3/pl unknown
- 2008-10-29 MX MX2010004841A patent/MX2010004841A/es active IP Right Grant
- 2008-10-29 KR KR1020127023660A patent/KR20120107145A/ko not_active Withdrawn
- 2008-10-29 KR KR1020107009633A patent/KR101335059B1/ko not_active Expired - Fee Related
- 2008-10-29 CN CN200880114428.1A patent/CN103492414B/zh not_active Expired - Fee Related
- 2008-10-29 US US12/260,125 patent/US7820163B2/en not_active Expired - Fee Related
- 2008-10-29 MY MYPI2010001992A patent/MY155708A/en unknown
- 2008-10-29 SI SI200830773T patent/SI2209806T1/sl unknown
- 2008-10-29 AU AU2008318850A patent/AU2008318850B2/en not_active Ceased
- 2008-10-29 RS RS20120466A patent/RS52592B/sr unknown
- 2008-10-29 EA EA201070553A patent/EA023406B1/ru not_active IP Right Cessation
- 2008-10-29 EP EP12172307.6A patent/EP2527368B1/en active Active
- 2008-10-29 BR BRPI0819211-1A patent/BRPI0819211A2/pt not_active IP Right Cessation
- 2008-10-29 CA CA2704527A patent/CA2704527C/en not_active Expired - Fee Related
- 2008-10-29 PT PT08844586T patent/PT2209806E/pt unknown
- 2008-10-29 NZ NZ598391A patent/NZ598391A/xx not_active IP Right Cessation
- 2008-10-29 EP EP08844586A patent/EP2209806B1/en active Active
- 2008-10-29 JP JP2010532186A patent/JP5469076B2/ja not_active Expired - Fee Related
- 2008-10-29 NZ NZ584997A patent/NZ584997A/en not_active IP Right Cessation
- 2008-10-29 WO PCT/US2008/081493 patent/WO2009058797A1/en not_active Ceased
- 2008-10-29 HR HRP20120870AT patent/HRP20120870T1/hr unknown
- 2008-10-29 DK DK08844586.1T patent/DK2209806T3/da active
- 2008-10-29 UA UAA201005156A patent/UA98983C2/uk unknown
2010
- 2010-04-22 CO CO10047542A patent/CO6231037A2/es active IP Right Grant
- 2010-04-26 DO DO2010000123A patent/DOP2010000123A/es unknown
- 2010-04-26 IL IL205355A patent/IL205355A/en not_active IP Right Cessation
- 2010-04-30 ZA ZA2010/03025A patent/ZA201003025B/en unknown
- 2010-04-30 TN TN2010000201A patent/TN2010000201A1/fr unknown
- 2010-04-30 MA MA32811A patent/MA31886B1/fr unknown
- 2010-05-05 CR CR11414A patent/CR11414A/es not_active IP Right Cessation
- 2010-08-31 US US12/872,172 patent/US8329174B2/en active Active
2012
- 2012-06-22 CL CL2012001710A patent/CL2012001710A1/es unknown
- 2012-10-19 CY CY20121100986T patent/CY1113630T1/el unknown
- 2012-12-07 US US13/708,059 patent/US8765129B2/en active Active
2013
- 2013-09-11 DO DO2013000205A patent/DOP2013000205A/es unknown

Also Published As

Publication number	Publication date
AR069062A1 (es)	2009-12-23
TWI409276B (zh)	2013-09-21
TN2010000201A1 (en)	2011-11-11
US20110027261A1 (en)	2011-02-03
DOP2010000123A (es)	2010-08-15
KR101335059B1 (ko)	2013-12-11
KR20120107145A (ko)	2012-09-28
NZ584997A (en)	2012-06-29
DOP2013000205A (es)	2013-12-15
CR11414A (es)	2010-08-05
ZA201003025B (en)	2011-11-30
HRP20120870T1 (hr)	2012-11-30
US20130164304A1 (en)	2013-06-27
HK1142341A1 (en)	2010-12-03
MX2010004841A (es)	2010-07-30
JO2828B1 (en)	2014-09-15
RS52592B (sr)	2013-04-30
EP2209806A1 (en)	2010-07-28
AU2008318850B2 (en)	2014-05-29
NZ598391A (en)	2013-07-26
EP2527368B1 (en)	2016-08-24
US8765129B2 (en)	2014-07-01
CA2704527C (en)	2015-12-15
CO6231037A2 (es)	2010-12-20
IL205355A0 (en)	2010-12-30
CA2704527A1 (en)	2009-05-07
CL2008003190A1 (es)	2009-09-04
PE20091261A1 (es)	2009-08-17
WO2009058797A1 (en)	2009-05-07
CN103492414A (zh)	2014-01-01
TW200927759A (en)	2009-07-01
PL2209806T3 (pl)	2013-01-31
UA98983C2 (uk)	2012-07-10
JP2011502482A (ja)	2011-01-27
MY155708A (en)	2015-11-13
IL205355A (en)	2015-05-31
KR20100067682A (ko)	2010-06-21
EP2209806B1 (en)	2012-08-22
EP2527368A1 (en)	2012-11-28
US8329174B2 (en)	2012-12-11
DK2209806T3 (da)	2012-09-17
MA31886B1 (fr)	2010-12-01
JP5469076B2 (ja)	2014-04-09
CN103492414B (zh)	2016-04-13
CY1113630T1 (el)	2016-06-22
SI2209806T1 (sl)	2012-11-30
ES2392123T3 (es)	2012-12-04
US7820163B2 (en)	2010-10-26
US20090136495A1 (en)	2009-05-28
AU2008318850A1 (en)	2009-05-07
EA201070553A1 (ru)	2010-10-29
PT2209806E (pt)	2012-10-03
CL2012001710A1 (es)	2013-04-12
EA023406B1 (ru)	2016-06-30

Publication	Publication Date	Title
BRPI0819211A2 (pt)	2015-06-16	Anticorpos de anti-hepcidina e usos dos mesmos, polinucleotídeo, vetor de expressão recombinante, processo para produzir um anticorpo, composição farmacêutica, imunoensaio e kit para a realização do mesmo
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
CL2014000400A1 (es)	2014-08-29	Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
BRPI0821447A2 (pt)	2015-06-16	Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
BR112012004221A2 (pt)	2016-11-29	"anticorpos, composição farmacêutica, uso do anticorpo, ácido nucleico, vetores de expressão, célula hospedeira procariótica e método para a produção de um anticorpo humanizado recombinante"
BRPI0717768A2 (pt)	2013-11-05	Anticorpo, epítipo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
BRPI0812400A2 (pt)	2014-10-29	Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
BRPI0816094A2 (pt)	2015-03-03	Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
BRPI0821375B8 (pt)	2021-05-25	anticorpos biespecíficos, bivalentes, processo para a preparação destes e composição farmacêutica dos mesmos
BRPI0905076A2 (pt)	2015-07-07	Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BR112012022046A2 (pt)	2017-02-14	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
BR112013029893A2 (pt)	2017-05-30	molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
BRPI0819688A2 (pt)	2015-06-16	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0822447A2 (pt)	2015-06-16	Anticorpo monoclonal e método do mesmo
BRPI0821682A2 (pt)	2015-06-16	Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
LT3656793T (lt)	2022-03-10	Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
BR112012003809A2 (pt)	2019-09-24	anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BRPI0923199A2 (pt)	2016-02-16	métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0818780A2 (pt)	2015-04-22	Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
BRPI0813645A2 (pt)	2014-12-30	Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
BRPI0808655A2 (pt)	2018-10-23	anticorpos monoclonais de he4 e métodos para a sua utilização.
CR10705A (es)	2009-05-07	Anticuerpos para linfotoxina-alfa
BRPI0817182A2 (pt)	2015-03-17	Método para purificar um anticorpo e composições
BRPI0916964A2 (pt)	2015-11-24	polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.